IL-17F Protein: Structure and Function, Signaling Pathways, and Clinical Targeting Significance

I. Molecular Structure and Expression Regulation

IL-17F exerts its biological functions either as a homodimer (IL-17F/IL-17F) or as a heterodimer with IL-17A (IL-17A/IL-17F).

Gene and Protein Structure:
The human IL17F gene is located on chromosome 6p12.2. Mature IL-17F protein is a ~35 kDa glycoprotein, with monomers linked by intermolecular disulfide bonds formed by conserved cysteine residues. Compared to IL-17A, it exhibits differences in the signal peptide sequence and N-glycosylation sites.

Expression and Secretion: IL-17F is primarily produced by activated CD4⁺ Th17 cells, and its expression is strictly regulated by the key transcription factor RORγt. Additionally, other immune cells such as mast cells, neutrophils, and epithelial cells can be induced to express IL-17F under specific stimuli.

Heterodimer:
The production, secretion, and biological activity of the IL-17A/IL-17F heterodimer typically fall between those of the two homodimers and may possess unique regulatory functions in inflammatory responses in vivo.

II. Receptor Complex and Signal Transduction Pathways

IL-17F signal transduction relies on its binding to specific receptor complexes on the cell surface.

Receptor Recognition: IL-17F primarily binds to a heterodimeric receptor complex composed of IL-17 receptor A (IL-17RA) and IL-17 receptor C (IL-17RC). The affinity of IL-17F for its receptors is generally lower than that of IL-17A, which may partially explain its relatively weaker pro-inflammatory activity in vitro.

Downstream Signaling:
Following ligand-receptor binding, the adaptor protein Act1 is recruited via the SEFIR domain in the intracellular region of the receptors. Act1 recruitment activates the following major pathways:

NF-κB Pathway: Activated through a TRAF6-dependent mechanism, driving the transcription of various inflammatory cytokine genes.

MAPK Pathway: Activates JNK, p38, and ERK, regulating cell stress, proliferation, and differentiation.

C/EBP Pathway: Also involved in inducing the expression of specific target genes.

Target Genes and Effects:
These signaling pathways ultimately synergize to induce the production of a series of effector molecules by epithelial cells, fibroblasts, and endothelial cells, including:

Chemokines: CXCL1, CXCL5, CXCL8 (IL-8), which recruit neutrophils.

Cytokines: GM-CSF, G-CSF.

Antimicrobial Peptides: β-defensin 2, S100 proteins.

Matrix Remodeling Enzymes: MMP3, MMP9.

III. Biological Functions and Pathophysiological Roles

The functions of IL-17F are tissue-specific and crucial in mucosal barrier defense and chronic inflammation.

Host Defense:
At mucosal surfaces (e.g., skin, lungs, intestines), IL-17F enhances early immune defense against extracellular bacteria (e.g., Staphylococcus aureus, Klebsiella pneumoniae) and fungi (e.g., Candida albicans) by inducing epithelial cells to produce antimicrobial peptides and chemokines.

Central Role in Inflammatory Diseases:

Psoriasis:
IL-17F synergizes with IL-17A to drive keratinocyte hyperproliferation and promote the production of inflammatory cytokines such as IL-1β and TNF-α, serving as a core driver of plaque psoriasis pathology.

Asthma:
In neutrophilic asthma, IL-17F promotes airway hyperresponsiveness, mucus hypersecretion, and neutrophilic inflammation.

Inflammatory Bowel Disease (IBD):
IL-17F expression is upregulated in intestinal inflammation in Crohn's disease and ulcerative colitis, but its role may be disease-stage and microenvironment-dependent, with some studies suggesting both pro-inflammatory and protective functions.

Autoimmune Diseases:
In rheumatoid arthritis, multiple sclerosis, and other diseases, IL-17F collaborates with IL-17A to mediate tissue inflammation and damage.

IV. Therapeutic Targeting Strategies and Current Status

Given the central role of the IL-17 pathway in various diseases, targeting IL-17F and its pathway has become a focus of therapeutic development.

Specific Neutralizing Antibodies:
Developing monoclonal antibodies that selectively neutralize IL-17F is one of the primary strategies. These drugs aim to more precisely inhibit IL-17F function while potentially preserving some of the host defense functions mediated by IL-17A, thereby achieving a better balance between efficacy and safety. Related drugs have entered clinical trials for psoriasis and asthma.

IL-17 Receptor Blockers:
Monoclonal antibodies targeting IL-17RA (e.g., brodalumab) can simultaneously block signaling from multiple ligands, including IL-17A and IL-17F, and have been approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, validating the effectiveness of this pathway as a target.

Small-Molecule Inhibitors:
Small-molecule inhibitors targeting downstream signaling molecules (e.g., Act1, RORγt) are also under development. RORγt inverse agonists can reduce the production of both IL-17A and IL-17F by inhibiting Th17 cell differentiation at the source.

V. Research Challenges and Future Directions

Current research faces several major challenges:

Functional Redundancy and Specificity:
How to precisely distinguish the contributions of IL-17F versus IL-17A in specific diseases to develop more targeted therapies.

Disease-Specific Roles:
IL-17F may exert paradoxical effects in different diseases or even at different stages of the same disease, necessitating a deeper understanding of its context-dependent functions.

Biomarkers:
Identifying biomarkers that can predict responses to anti-IL-17F therapies to enable personalized treatment.

Future research will focus on elucidating the precise mechanisms of IL-17F in specific tissue microenvironments, exploring its synergistic networks with other cytokines (e.g., TNF-α, IL-23), and developing more effective combination therapies.

In summary

IL-17F is an indispensable member of the IL-17 cytokine family, with independent and important functions in mucosal immunity and chronic inflammatory diseases. As our understanding of its biological properties deepens, IL-17F is transforming from a key inflammatory mediator into a highly promising target for precision therapy. Drugs targeting IL-17F may provide new treatment options for patients who respond inadequately to or cannot tolerate existing anti-IL-17A/IL-17RA therapies.